dstock - The timing of the combo clinical trial updates using Keytrtuda in combination with ATL-DC aka DCVAX is interesting. Northwest had its checkpoint/dendritic cell combo patent approved right around that time.
To answer your question, what did the NIH and DHHS do with the assignment? It was abandoned, and since, an improved iteration was granted to Northwest et al. It's also interesting to see earlier combination work and Revimmune named among patent holders.
There seems to be "a lot more than meets the eye" from all these convergences and timing, no doubt about that. To your point, these are just nuggets picked up from what's publicly available. Imagine the size and scope of what's brewing behind the scenes. LP appears to have embraced the classic "Art of War" doctrine. The vultures chose to keep circling the wagon in hopes of seeing NWBO fail. I'll go so far as to say, obsessed by virtue of their shear relentlessness. The drama that ensued around NWBO, as an ongoing concern lulled BP to sleep. As can be seen by all the previous art ip grants, connections, and collaborations, including but not limited to Gov't Health and Military agency grants and or cooperation, LP has been planning and scheming for YEARS, and, as in the Art of War, catching the opposition by surprise is what wins the day.
Market Data 
Markets 
AI
